annual accounts payable:
$9.03M+$1.99M(+28.26%)Summary
- As of today (July 1, 2025), AKRO annual accounts payable is $9.03 million, with the most recent change of +$1.99 million (+28.26%) on December 31, 2024.
- During the last 3 years, AKRO annual accounts payable has risen by +$2.32 million (+34.61%).
- AKRO annual accounts payable is now at all-time high.
Performance
AKRO Accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly accounts payable:
$10.83M+$1.80M(+19.98%)Summary
- As of today (July 1, 2025), AKRO quarterly accounts payable is $10.83 million, with the most recent change of +$1.80 million (+19.98%) on March 31, 2025.
- Over the past year, AKRO quarterly accounts payable has dropped by -$2.95 million (-21.42%).
- AKRO quarterly accounts payable is now -57.06% below its all-time high of $25.22 million, reached on September 30, 2024.
Performance
AKRO quarterly accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
AKRO Accounts payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +28.3% | -21.4% |
3 y3 years | +34.6% | +143.4% |
5 y5 years | +853.2% | +605.6% |
AKRO Accounts payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +34.6% | -57.1% | +80.2% |
5 y | 5-year | at high | +853.2% | -57.1% | +369.5% |
alltime | all time | at high | >+9999.0% | -57.1% | >+9999.0% |
AKRO Accounts payable History
Date | Annual | Quarterly |
---|---|---|
Mar 2025 | - | $10.83M(+20.0%) |
Dec 2024 | $9.03M(+28.3%) | $9.03M(-64.2%) |
Sep 2024 | - | $25.22M(+73.1%) |
Jun 2024 | - | $14.57M(+5.7%) |
Mar 2024 | - | $13.78M(+95.8%) |
Dec 2023 | $7.04M(-11.7%) | $7.04M(-38.6%) |
Sep 2023 | - | $11.45M(+13.2%) |
Jun 2023 | - | $10.12M(+43.0%) |
Mar 2023 | - | $7.08M(-11.1%) |
Dec 2022 | $7.97M(+18.8%) | $7.97M(+32.6%) |
Sep 2022 | - | $6.01M(-12.6%) |
Jun 2022 | - | $6.88M(+54.5%) |
Mar 2022 | - | $4.45M(-33.6%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2021 | $6.71M(+95.6%) | $6.71M(-1.1%) |
Sep 2021 | - | $6.78M(+194.1%) |
Jun 2021 | - | $2.31M(-49.9%) |
Mar 2021 | - | $4.61M(+34.3%) |
Dec 2020 | $3.43M(+262.0%) | $3.43M(-26.1%) |
Sep 2020 | - | $4.64M(+82.8%) |
Jun 2020 | - | $2.54M(+65.2%) |
Mar 2020 | - | $1.53M(+62.1%) |
Dec 2019 | $947.00K(-31.0%) | $947.00K(+918.3%) |
Sep 2019 | - | $93.00K(-97.1%) |
Jun 2019 | - | $3.25M(+241.2%) |
Mar 2019 | - | $952.00K(-30.7%) |
Dec 2018 | $1.37M(+2188.3%) | $1.37M |
Dec 2017 | $60.00K | - |
FAQ
- What is Akero Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Akero Therapeutics?
- What is Akero Therapeutics annual accounts payable year-on-year change?
- What is Akero Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Akero Therapeutics?
- What is Akero Therapeutics quarterly accounts payable year-on-year change?
What is Akero Therapeutics annual accounts payable?
The current annual accounts payable of AKRO is $9.03M
What is the all time high annual accounts payable for Akero Therapeutics?
Akero Therapeutics all-time high annual accounts payable is $9.03M
What is Akero Therapeutics annual accounts payable year-on-year change?
Over the past year, AKRO annual accounts payable has changed by +$1.99M (+28.26%)
What is Akero Therapeutics quarterly accounts payable?
The current quarterly accounts payable of AKRO is $10.83M
What is the all time high quarterly accounts payable for Akero Therapeutics?
Akero Therapeutics all-time high quarterly accounts payable is $25.22M
What is Akero Therapeutics quarterly accounts payable year-on-year change?
Over the past year, AKRO quarterly accounts payable has changed by -$2.95M (-21.42%)